Navigation Links
AstraZeneca Initiates Phase 3 Clinical Trial For Selumetinib In Non-Small Cell Lung Cancer
Date:10/22/2013

o of 1:1 to receive either selumetinib (75mg, orally, twice daily) or matching placebo in combination with docetaxel (intravenously, 75mg / m2, on day one of every 21 day cycle).  SELECT-1 will be the largest prospective study ever conducted in this patient population, a genetic sub-type of lung cancer associated with poor prognosis and limited treatment options. 

AstraZeneca's decision to progress selumetinib to Phase 3 in NSCLC followed the results from a randomized Phase 2 study evaluating the combination of selumetinib with docetaxel against docetaxel alone in KRAS-mutation positive NSCLC. This study demonstrated a high and durable response rate of 37.2% vs 0% (p<0.0001), translating into a statistically significant improvement in PFS of 5.3 vs 2.1 months (HR 0.58, p<0.014).

Antoine Yver, Vice President and Head of Oncology in AstraZeneca's Global Medicines Development unit said: "To our knowledge, SELECT-1 will be the first Phase 3 study to investigate whether a MEK inhibitor in combination with chemotherapy is superior to chemotherapy alone in advanced or metastatic non-small cell lung cancer.  This is an area of pressing clinical need, and our decision to progress selumetinib was based on Phase 2 results, which showed promising clinical activity in this group of patients." 

AstraZeneca is also investigating the potential for selumetinib in several types of MEK-dependent cancers.  A pivotal Phase 2 study assessing the efficacy and tolerability of selumetinib combined with radioactive iodine (RAI) as adjuvant therapy in patients with differentiated thyroid cancer with high risk of recurrence started in August 2013, and a further Phase 2 study assessing the clinical efficacy and tolerability in combination with dacarbazine in patients with metastatic uveal melanoma is planned to start in late 2013.

About selumetinib
Selumetinib is an oral, potent, selective ME
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
2. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
3. Omthera Stockholders Approve Acquisition by AstraZeneca
4. AstraZeneca Neuroscience partners with ePharmaSolutions to optimize Clinical Trial Management
5. Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
6. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
7. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
8. AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
9. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
10. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
11. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... NEW YORK , July 31, 2015  Seeger Weiss ... Drug Administration (FDA) issued a warning letter to C.R. Bard, ... for not taking adequate strides to correct violations the agency ... aware of these violations after the FDA cited them during ... 05, 2015, in Bard,s Tempe, AZ , ...
(Date:7/31/2015)... 2015 Today, the National Association of ... issued a report urging greater accountability by the ... against websites illegally selling medications online. As detailed ... Program Progress Report for State and Federal Regulators: ... websites illegally distribute medications and avoid retribution. Such ...
(Date:7/31/2015)... , July 31, 2015 The ... press release on July 28, 2015, "Surviving Your ... Launches Fundraising for Patient Safety." A ... sentence should read: "PPAHS is a ... Patients on Opioids. For more information on the National ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3
... 3, 2012  Omeros Corporation (NASDAQ: OMER ) ... interact with each of four additional orphan G protein-coupled ... GPCRs, developing drugs targeting those receptors is extremely difficult. ... 45 percent of the Class A orphan GPCRs. There ...
... 2012 /PRNewswire-Asia/ -- Johnson & Johnson (China) ... Guangzhou Bioseal Biotechnology Co., Ltd. (Bioseal) a ... design, development and commercialization of a porcine ... surgery. The acquisition was completed after obtaining ...
Cached Medicine Technology:Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio 2Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio 3Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio 4Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd. 2
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down ... is currently going on in Chicago at Grant Park. The festival will end ... of North America to Chicago for the annual Lollapalooza. This unique and unbelievably ...
(Date:7/31/2015)... ... 31, 2015 , ... Last week, the Mesothelioma Applied Research ... be accessed by visiting http://www.curemeso.org/store . , “Our new store features a ... whenever a product is purchased, the Meso Foundation receives a $5.00 donation,” said ...
(Date:7/31/2015)... ... July 31, 2015 , ... There’s no better way to ... it comes time to cook the next meal, making July the most appropriate to ... best grilling tips and recipes. , Make the next cookout different than the ones ...
(Date:7/31/2015)... ... 31, 2015 , ... Coco Libre announced today that their flagship Organic Coconut ... 2015 Vans US Open of Surfing, July 25 through August 2 in Huntington Beach, ... on the market, is a natural choice given the Open’s commitment to sustainable practices. ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2
... With More than 1,000 Reported Incidents, Caregivers Call ... SAN FRANCISCO, Aug. 31 Home care workers ... organization seeking to decertify the workers, union, saying they had been ... The home caregivers, members of the Service Employees International Union, ...
... ... claim, but has now reversed decision and will cover patient,s life flight , ... Scottsdale, AZ (PRWEB) August 31, 2009 -- ... life flight transportation to be evaluated for a liver transplant. Her doctors told ...
... , SAN FRANCISCO, Aug. 31 /PRNewswire/ ... agency staffed with seasoned marketing professionals and a division of Omnicom,s ... to the position of Director of Strategy for their growing healthcare ... to ECI CEO and President Bara Oscodar. , , ...
... , , LAKE FOREST, ... the world leader in generic injectable pharmaceuticals, today announced that the ... for six new presentations of therapeutic heparin in single- and multiple-dose ... clot formation in central venous catheters and for anticoagulant (blood thinning) ...
... , SCOTTSDALE, Ariz., Aug. 31 Last year, ... of life flight transportation to be evaluated for ... evaluation in order to get on the transplant list. Travel by ground ... Her health insurance company told her they would not cover the ...
... , , , , ... San Diego-based MultiGEN Diagnostics Inc. has launched a novel multi-target DNA ... testing in molecular diagnostics. , , "Until now, ... diagnostic market, forcing laboratories to adopt number of alternative methods such ...
Cached Medicine News:Health News:San Francisco Home Care Workers Describe Lies, Coercion, and Fraud in Union Signature Drive 2Health News:San Francisco Home Care Workers Describe Lies, Coercion, and Fraud in Union Signature Drive 3Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 3Health News:ECI Hires Robin Raff as Director of Strategy 2Health News:Hospira Receives FDA Approval for Six New Presentations of Heparin 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 3Health News:Cost Effective Solution for Patient Testing: Introducing Comprehensive and Affordable Molecular Diagnosis With Verifiable Accuracy 2
Low-profile, hand-held instrument....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
... The Small Fragment Plate and Screw System provides ... wide range on angular deformities; particularly the opening ... hallux valgus correction). The Small Fragment Plate and ... with a removable caddy that houses the plates, ...
Medicine Products: